Contreras, Cristina M <br/><br/>
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.  [electronic resource] 

 -  Disease models & mechanisms   
 - 181-93 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1754-8411 
<br/><br/><label>Standard No.: </label>10.1242/dmm.004440  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinases<br/>Animals<br/>Cell Line, Tumor<br/>Cloning, Molecular<br/>Cornified Envelope Proline-Rich Proteins--genetics<br/>Disease Models, Animal<br/>Drug Screening Assays, Antitumor<br/>Endometrial Neoplasms--drug therapy<br/>Endometrium--drug effects<br/>Enzyme Activation--drug effects<br/>Epithelium--drug effects<br/>Female<br/>Integrases--metabolism<br/>Intracellular Signaling Peptides and Proteins--antagonists & inhibitors<br/>Mice<br/>Mice, Transgenic<br/>Neoplasm Invasiveness<br/>Organ Specificity--drug effects<br/>Penetrance<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Response Elements--genetics<br/>Sirolimus--pharmacology<br/>TOR Serine-Threonine Kinases